Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

South Africa's Aspen Pharmacare FY profit up 13 pct

Published 09/09/2015, 10:00 pm
Updated 09/09/2015, 10:07 pm
© Reuters.  South Africa's Aspen Pharmacare FY profit up 13 pct
APNJ
-

JOHANNESBURG, Sept 9 (Reuters) - South African drugmaker Aspen Pharmacare's APNJ.J full-year profit growth slowed to 13 percent, weighed down by currency volatility, the company said on Wednesday.

Aspen, which supplies drugs to about 150 countries, including the United States, Australia and most of Latin America, said diluted headline earnings per share was 1,149.7 cents to end-June from 1,016.1 cents the year earlier.

Headline EPS is the most widely watched profit measure in South Africa and strips out certain one-off items.

The company has grown rapidly after expanding outside its highly regulated home market, increasing profits by more than 25 percent each year since 2012.

"The group remains exposed to the strength of the U.S. dollar against its primary trading currencies," Aspen said in a statement.

The company imports many of its drug-making ingredients and pays using the euro, South Africa's rand and the Australian dollar, meaning that a stronger U.S. dollar erodes its earnings.

The rand and the Australian dollar have both lost more than 13 percent against the greenback so far this year, while the euro has weakened by about 8 percent.

Aspen's shares were up 2.93 percent to 335.50 rand by 1155 GMT, against a 1.25 percent gain by the JSE's benchmark Top-40 index.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.